JP2022505923A5 - - Google Patents
Info
- Publication number
- JP2022505923A5 JP2022505923A5 JP2021523009A JP2021523009A JP2022505923A5 JP 2022505923 A5 JP2022505923 A5 JP 2022505923A5 JP 2021523009 A JP2021523009 A JP 2021523009A JP 2021523009 A JP2021523009 A JP 2021523009A JP 2022505923 A5 JP2022505923 A5 JP 2022505923A5
- Authority
- JP
- Japan
- Prior art keywords
- invention described
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862754378P | 2018-11-01 | 2018-11-01 | |
| US62/754,378 | 2018-11-01 | ||
| PCT/US2019/059556 WO2020093024A2 (en) | 2018-11-01 | 2019-11-01 | Methods of administering anti-tim-3 antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022505923A JP2022505923A (ja) | 2022-01-14 |
| JP2022505923A5 true JP2022505923A5 (enExample) | 2022-11-08 |
Family
ID=69159932
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021523009A Pending JP2022505923A (ja) | 2018-11-01 | 2019-11-01 | 抗ｔｉｍ－３抗体を投与する方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220073616A1 (enExample) |
| EP (1) | EP3873612A2 (enExample) |
| JP (1) | JP2022505923A (enExample) |
| CN (1) | CN113301961A (enExample) |
| AU (1) | AU2019372436A1 (enExample) |
| CA (1) | CA3117371A1 (enExample) |
| IL (1) | IL282708A (enExample) |
| WO (1) | WO2020093024A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200231652A1 (en) | 2015-08-31 | 2020-07-23 | National Research Council Of Canada | Tgf-b-receptor ectodomain fusion molecules and uses thereof |
| AU2018228435C1 (en) | 2017-03-02 | 2025-09-18 | National Research Council Of Canada | TGF-beta-receptor ectodomain fusion molecules and uses thereof |
| JP2023532279A (ja) * | 2020-06-26 | 2023-07-27 | ソレント・セラピューティクス・インコーポレイテッド | 免疫調節性融合タンパク質を発現する腫瘍溶解性単純ヘルペスウイルス（ｈｓｖ） |
| CN117120091A (zh) * | 2021-04-13 | 2023-11-24 | 免疫医疗有限责任公司 | 靶向pd-1和tim-3的双特异性抗体 |
| EP4326773A4 (en) | 2021-04-23 | 2025-09-24 | Suzhou Neologics Bioscience Co Ltd | ANTIBODIES TARGETING TIM-3 AND THEIR USES |
| WO2022271917A1 (en) * | 2021-06-24 | 2022-12-29 | Bristol-Myers Squibb Company | Transforming growth factor-beta ligand traps for the treatment of disease |
| CN116688115B (zh) * | 2022-03-18 | 2024-02-06 | 上海齐鲁制药研究中心有限公司 | 一种PD-L1/TGF-β双功能融合蛋白制剂及其用途 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0204475A2 (en) | 2000-02-11 | 2003-04-28 | Merck Patent Gmbh | Enhancing the circulating half-life of antibody-based fusion proteins |
| RU2003129528A (ru) | 2001-03-07 | 2005-04-10 | Мерк Патент ГмбХ (DE) | Способ экспрессии белков, содержащих в качестве компонента гибридный изотип антитела |
| WO2002079415A2 (en) | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
| ES2413087T3 (es) * | 2006-06-13 | 2013-07-15 | Oncomed Pharmaceuticals, Inc. | Composiciones y métodos para el diagnóstico y tratamiento del cáncer |
| CA3253628A1 (en) | 2010-03-05 | 2025-11-29 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
| WO2013006490A2 (en) * | 2011-07-01 | 2013-01-10 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to tim3 |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| HUE045065T2 (hu) * | 2014-01-31 | 2019-12-30 | Novartis Ag | TIM-3 antitest molekulák és felhasználásaik |
| BR112016014952A2 (pt) * | 2014-02-10 | 2017-09-19 | Merck Patent Gmbh | Inibição direcionada de tgfbeta |
| SMT202000265T1 (it) * | 2014-07-11 | 2020-07-08 | Genmab As | Anticorpi che legano axl |
| EP4245376A3 (en) * | 2014-10-14 | 2023-12-13 | Novartis AG | Antibody molecules to pd-l1 and uses thereof |
| TWI595006B (zh) * | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| EP3878465A1 (en) * | 2015-07-29 | 2021-09-15 | Novartis AG | Combination therapies comprising antibody molecules to tim-3 |
| US10077308B2 (en) * | 2016-06-13 | 2018-09-18 | Askgene Pharma Inc. | PD-L1 specific monoclonal antibodies for disease treatment and diagnosis |
| CN109640988A (zh) * | 2016-06-21 | 2019-04-16 | X4 制药有限公司 | Cxcr4抑制剂及其用途 |
| JOP20190013A1 (ar) * | 2016-08-25 | 2019-01-31 | Lilly Co Eli | أجسام مضادة لـ (تي آي ام -3) |
| MX2019005116A (es) * | 2016-11-01 | 2019-11-12 | Anaptysbio Inc | Anticuerpos dirigidos contra la proteina de inmunoglobulina de linfocitos t y de mucina 3 (tim-3). |
| TW201825513A (zh) * | 2016-11-29 | 2018-07-16 | 美商提薩羅有限公司 | 針對ｔ細胞免疫球蛋白及黏蛋白３（ｔｉｍ-３）之抗體 |
| MY202480A (en) | 2017-05-12 | 2024-04-30 | Shanghai hengrui pharmaceutical co ltd | Fusion protein containing tgf- receptor and medicinal uses thereof |
-
2019
- 2019-11-01 AU AU2019372436A patent/AU2019372436A1/en not_active Abandoned
- 2019-11-01 WO PCT/US2019/059556 patent/WO2020093024A2/en not_active Ceased
- 2019-11-01 JP JP2021523009A patent/JP2022505923A/ja active Pending
- 2019-11-01 EP EP19835890.5A patent/EP3873612A2/en not_active Withdrawn
- 2019-11-01 CN CN201980086650.3A patent/CN113301961A/zh active Pending
- 2019-11-01 CA CA3117371A patent/CA3117371A1/en active Pending
-
2021
- 2021-04-27 IL IL282708A patent/IL282708A/en unknown
- 2021-04-30 US US17/245,476 patent/US20220073616A1/en not_active Abandoned